Trial
NCT06769555
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
UnknownWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Collaborators
Keymed Biosciences Co.Ltd
Condition
AL Amyloidosis
Intervention
CM-336 BCMA/CD3 bispecific antibody
Why stopped
The study protocol was withdrawn because, after modifications, the study transitioned from an Investigator-Initiated Trial (IIT) to an Investigational New Drug (IND) clinical trial. This change necessitated a multi-center approach.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-29